Anchored in the observation that patients often struggle to adhere to their treatment regimens -- undermining medical care, putting outcomes at risk, and increasing overall healthcare costs, both directly and indirectly. Lyndra Inc is organized around tackling the way patients take medicine. For decades, the effort has been underway to develop extended drug release technology, but current oral formulations on the market only extend delivery by 12 to 24 hours. The Lyndra team -- comprised of MIT and Harvard scientists and physician scientists -- has for the first time developed a technology that extends oral drug delivery beyond one week. Fundamentally aiming to change the way patients take medicines through the development of oral, ultra-long-acting, sustained release oral therapies that drastically improve healthcare outcomes. the Lyndra technology was developed at the Massachusetts Institute of Technology, in the laboratory of Dr. Robert Langer in collaboration with the Bill and Melinda Gates Foundation. Lyndra formulations transform medications taken daily or more frequently into a weekly or monthly dose, promising to improve patient adherence as well as to optimize the pharmacokinetic profile of the dosage form.
